CNV may also be treated with photodynamic therapy (PDT) coupled with a photosensitive drug such as verteporfin (Visudyne). The drug is given intravenously. It is then activated in the eye by a laser light. The drug destroys the new blood vessels, and prevents any new vessels forming by forming thrombi. A Cochrane Review published in 2016 found that people with severe myopia (short-sightedness or near-sightedness) may benefit from being given anti-VEGF treatment.
